SCHEMBL6624327

SCHEMBL6624327

Cc1cnn(-c2ccc(C(=O)Cl)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MGLL Q99685 1/20 0.45
MAP4K4 O95819 1/20 0.44
HPGDS O60760 1/20 0.44
ALKBH2 Q6NS38 1/20 0.44
ALOX5AP P20292 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
GCGR P47871 1/20 0.41
HTT P42858 1/20 0.41
EGFR P00533 2/20 0.40
FGFR1 P11362 2/20 0.40
KDR P35968 2/20 0.40
CYP1A2 P05177 1/20 0.40
NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6624522 0.85 HPGDS (0.57) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL29949826 0.83 MAP4K4 (0.58) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL8297461 0.80 GSK3B (0.54) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL7028384 0.78 MAPT (0.47) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL9134518 0.77 ALDH1A1 (0.49) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL12988820 0.77 MELK (0.50) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL16467066 0.75 NPC1 (0.61) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL31227412 0.73 MAOA (0.44) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL30882345 0.73 HPGDS (0.51) MAPTHPGDNPC1RAB9AKDM4E
SCHEMBL12349894 0.73 GRM4 (0.43) MAPTHPGDNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1183134-C Tricyclic vasopressin agonists 2005-01-05 CN disclosed
US-6831079-B1 Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone AMERICAN CYANAMID COMPANY 2004-12-14 US disclosed
EP-1000062-B1 TRICYCLIC VASOPRESSIN AGONISTS WYETH CORP (US) 2004-09-22 EP disclosed
US-6511974-B1 Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure WYETH 2003-01-28 US disclosed
CN-1391476-A Vasopressin agonist formulation and process AMERICAN CYANAMID CO (US) 2003-01-15 CN disclosed
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 EP disclosed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 WO disclosed
CN-1272111-A Tricyclic vasopressin agonists AMERICAN HOME PROD (US) 2000-11-01 CN disclosed
EP-1000062-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
WO-1999006409-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed